Cargando…
New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient
The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), still remains a severe threat. At the time of writing this paper, the second infectious wave has caused more than 280,000 deaths all over the world. Italy was one of the first countries involved, with more...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778886/ https://www.ncbi.nlm.nih.gov/pubmed/35055400 http://dx.doi.org/10.3390/jpm12010085 |
_version_ | 1784637438569742336 |
---|---|
author | Balzanelli, Mario Giosuè Distratis, Pietro Lazzaro, Rita D’Ettorre, Ernesto Nico, Andrea Inchingolo, Francesco Dipalma, Gianna Tomassone, Diego Serlenga, Emilio Maria Dalagni, Giancarlo Ballini, Andrea Nguyen, Kieu Cao Diem Isacco, Ciro Gargiulo |
author_facet | Balzanelli, Mario Giosuè Distratis, Pietro Lazzaro, Rita D’Ettorre, Ernesto Nico, Andrea Inchingolo, Francesco Dipalma, Gianna Tomassone, Diego Serlenga, Emilio Maria Dalagni, Giancarlo Ballini, Andrea Nguyen, Kieu Cao Diem Isacco, Ciro Gargiulo |
author_sort | Balzanelli, Mario Giosuè |
collection | PubMed |
description | The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), still remains a severe threat. At the time of writing this paper, the second infectious wave has caused more than 280,000 deaths all over the world. Italy was one of the first countries involved, with more than 200,000 people reported as infected and 30,000 deaths. There are no specific treatments for COVID-19 and the vaccine still remains somehow inconclusive. The world health community is trying to define and share therapeutic protocols in early and advanced clinical stages. However, numbers remain critical with a serious disease rate of 14%, ending with sepsis, acute respiratory distress syndrome (ARDS), multiple organ failure (MOF) and vascular and thromboembolic findings. The mortality rate was estimated within 2–3%, and more than double that for individuals over 65 years old; almost one patient in three dies in the Intensive Care Unit (ICU). Efforts for effective solutions are underway with multiple lines of investigations, and health authorities have reported success treating infected patients with donated plasma from survivors of the illness, the proposed benefit being protective antibodies formed by the survivors. Plasma transfusion, blood and stem cells, either autologous or allograft transplantation, are not novel therapies, and in this short paper, we propose therapeutic autologous plasma and peripheral blood stem cells as a possible treatment for fulminant COVID-19 infection. |
format | Online Article Text |
id | pubmed-8778886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87788862022-01-22 New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient Balzanelli, Mario Giosuè Distratis, Pietro Lazzaro, Rita D’Ettorre, Ernesto Nico, Andrea Inchingolo, Francesco Dipalma, Gianna Tomassone, Diego Serlenga, Emilio Maria Dalagni, Giancarlo Ballini, Andrea Nguyen, Kieu Cao Diem Isacco, Ciro Gargiulo J Pers Med Case Report The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), still remains a severe threat. At the time of writing this paper, the second infectious wave has caused more than 280,000 deaths all over the world. Italy was one of the first countries involved, with more than 200,000 people reported as infected and 30,000 deaths. There are no specific treatments for COVID-19 and the vaccine still remains somehow inconclusive. The world health community is trying to define and share therapeutic protocols in early and advanced clinical stages. However, numbers remain critical with a serious disease rate of 14%, ending with sepsis, acute respiratory distress syndrome (ARDS), multiple organ failure (MOF) and vascular and thromboembolic findings. The mortality rate was estimated within 2–3%, and more than double that for individuals over 65 years old; almost one patient in three dies in the Intensive Care Unit (ICU). Efforts for effective solutions are underway with multiple lines of investigations, and health authorities have reported success treating infected patients with donated plasma from survivors of the illness, the proposed benefit being protective antibodies formed by the survivors. Plasma transfusion, blood and stem cells, either autologous or allograft transplantation, are not novel therapies, and in this short paper, we propose therapeutic autologous plasma and peripheral blood stem cells as a possible treatment for fulminant COVID-19 infection. MDPI 2022-01-10 /pmc/articles/PMC8778886/ /pubmed/35055400 http://dx.doi.org/10.3390/jpm12010085 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Balzanelli, Mario Giosuè Distratis, Pietro Lazzaro, Rita D’Ettorre, Ernesto Nico, Andrea Inchingolo, Francesco Dipalma, Gianna Tomassone, Diego Serlenga, Emilio Maria Dalagni, Giancarlo Ballini, Andrea Nguyen, Kieu Cao Diem Isacco, Ciro Gargiulo New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient |
title | New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient |
title_full | New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient |
title_fullStr | New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient |
title_full_unstemmed | New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient |
title_short | New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient |
title_sort | new translational trends in personalized medicine: autologous peripheral blood stem cells and plasma for covid-19 patient |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778886/ https://www.ncbi.nlm.nih.gov/pubmed/35055400 http://dx.doi.org/10.3390/jpm12010085 |
work_keys_str_mv | AT balzanellimariogiosue newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT distratispietro newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT lazzarorita newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT dettorreernesto newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT nicoandrea newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT inchingolofrancesco newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT dipalmagianna newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT tomassonediego newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT serlengaemiliomaria newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT dalagnigiancarlo newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT balliniandrea newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT nguyenkieucaodiem newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient AT isaccocirogargiulo newtranslationaltrendsinpersonalizedmedicineautologousperipheralbloodstemcellsandplasmaforcovid19patient |